CN104869983A - 醋酸格拉替雷的透粘膜给药 - Google Patents

醋酸格拉替雷的透粘膜给药 Download PDF

Info

Publication number
CN104869983A
CN104869983A CN201380067083.XA CN201380067083A CN104869983A CN 104869983 A CN104869983 A CN 104869983A CN 201380067083 A CN201380067083 A CN 201380067083A CN 104869983 A CN104869983 A CN 104869983A
Authority
CN
China
Prior art keywords
oral tablet
tablet
weight
present
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380067083.XA
Other languages
English (en)
Chinese (zh)
Inventor
厄休拉·杰斯特
斯蒂芬·施威策尔
玛蒂娜·伯格
拉尔夫·斯蒂芬
杰拉德·休伯
坦娅·普利斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of CN104869983A publication Critical patent/CN104869983A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Physiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201380067083.XA 2012-12-21 2013-12-20 醋酸格拉替雷的透粘膜给药 Pending CN104869983A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261745226P 2012-12-21 2012-12-21
US61/745,226 2012-12-21
PCT/US2013/077034 WO2014100639A1 (en) 2012-12-21 2013-12-20 Transmucosal delivery of glatiramer acetate

Publications (1)

Publication Number Publication Date
CN104869983A true CN104869983A (zh) 2015-08-26

Family

ID=50979257

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380067083.XA Pending CN104869983A (zh) 2012-12-21 2013-12-20 醋酸格拉替雷的透粘膜给药

Country Status (15)

Country Link
US (1) US20160193276A1 (https=)
EP (1) EP2934492A4 (https=)
JP (1) JP2016503803A (https=)
KR (1) KR20150111918A (https=)
CN (1) CN104869983A (https=)
AU (1) AU2013361053A1 (https=)
BR (1) BR112015014095A2 (https=)
CA (1) CA2895359A1 (https=)
EA (1) EA201591188A1 (https=)
HK (2) HK1214134A1 (https=)
IL (1) IL239280A0 (https=)
MX (1) MX2015007678A (https=)
SG (1) SG11201504422XA (https=)
WO (1) WO2014100639A1 (https=)
ZA (1) ZA201505049B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106924175A (zh) * 2015-12-29 2017-07-07 深圳翰宇药业股份有限公司 一种治疗多发性硬化症的药物组合物

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ703122A (en) 2010-10-11 2016-06-24 Teva Pharma Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate
KR20140101730A (ko) 2011-10-10 2014-08-20 테바 파마슈티컬 인더스트리즈 리미티드 글라티라머 아세테이트에 대한 임상 반응을 예측하는 데 유용한 단일 뉴클레오티드 다형성
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
WO2015140790A1 (en) 2014-03-17 2015-09-24 Mapi Pharma Ltd. Sublingual delivery of glatiramer acetate
HK1257053A1 (zh) * 2016-02-12 2019-10-11 特一华制药株式会社 干法制粒物和含有该干法制粒物的固态制剂及它的制造方法
JP2020525459A (ja) 2017-06-26 2020-08-27 アンスティテュ・パストゥール Ｈｉｖリザーバーを排除し、ウイルス負荷を低減する処置

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010055568A1 (en) * 2000-02-18 2001-12-27 Adrian Gilbert Oral, nasal and pulmonary dosage formulations of copolymer 1
US20030143257A1 (en) * 2001-07-10 2003-07-31 Moshe Fleshner-Barak Drug delivery system for zero order, zero order-biphasic, ascending or descending drug delivery

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001060392A1 (en) * 2000-02-18 2001-08-23 Yeda Research And Development Co., Ltd. At The Weizmann Institute Of Science Oral, nasal and pulmonary dosage formualtions of copolymer 1
PL1848415T3 (pl) * 2005-02-17 2013-10-31 Teva Pharma Terapia kombinowana obejmująca octan glatirameru oraz rasagilinę do leczenia stwardnienia rozsianego
WO2007061415A1 (en) * 2005-11-22 2007-05-31 Teva Pharmaceutical Industries Ltd. Pharmaceutical compositions of telmisartan
JP2009521523A (ja) * 2005-12-27 2009-06-04 ジュビラント・オルガノシス・リミテッド 口中溶解性医薬組成物およびその製造方法
BRPI0622054B8 (pt) * 2006-09-22 2021-05-25 Oxford Amherst Llc composto e composição farmacêutica
ES2329327B1 (es) * 2008-03-19 2010-09-17 Proyecto De Biomedicina Cima, S.L. Combinaciones sinergicas de 5'-metiltioadenosina.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010055568A1 (en) * 2000-02-18 2001-12-27 Adrian Gilbert Oral, nasal and pulmonary dosage formulations of copolymer 1
US20030143257A1 (en) * 2001-07-10 2003-07-31 Moshe Fleshner-Barak Drug delivery system for zero order, zero order-biphasic, ascending or descending drug delivery

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
庄越，曹宝成等: "《实用药物制剂技术》", 31 January 1999, 人民卫生出版社 *
罗明生，高天惠: "《药剂辅料大全》", 31 March 1993, 四川科学技术出版社 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106924175A (zh) * 2015-12-29 2017-07-07 深圳翰宇药业股份有限公司 一种治疗多发性硬化症的药物组合物
CN106924175B (zh) * 2015-12-29 2020-07-03 深圳翰宇药业股份有限公司 一种治疗多发性硬化症的药物组合物

Also Published As

Publication number Publication date
HK1214134A1 (zh) 2016-07-22
EP2934492A1 (en) 2015-10-28
US20160193276A1 (en) 2016-07-07
CA2895359A1 (en) 2014-06-26
MX2015007678A (es) 2015-09-07
EP2934492A4 (en) 2016-08-17
SG11201504422XA (en) 2015-07-30
WO2014100639A1 (en) 2014-06-26
JP2016503803A (ja) 2016-02-08
KR20150111918A (ko) 2015-10-06
BR112015014095A2 (pt) 2017-07-11
ZA201505049B (en) 2016-10-26
HK1214523A1 (zh) 2016-07-29
AU2013361053A1 (en) 2015-07-30
IL239280A0 (en) 2015-07-30
EA201591188A1 (ru) 2016-04-29

Similar Documents

Publication Publication Date Title
CN104869983A (zh) 醋酸格拉替雷的透粘膜给药
ES2507579T3 (es) Composición farmacéutica para el tratamiento del insomnio mediante administración sublingual
RU2404750C2 (ru) Композиция, содержащая основу или покрытие для замедленного высвобождения и антагонист nmda рецептора, способ введения такого nmda антагониста субъекту
AU2007287549B2 (en) Galenic formulations of aliskiren
TW200815048A (en) Methods for buccal, lingual or sublingual dosing regimens of epinephrine for the treatment of allergic emergencies
US20050084530A1 (en) Rapid acting freeze dried oral pharmaceutical composition for treating migraine
JP2013509403A (ja) 速溶性固体剤形
WO2007096906A2 (en) Novel buccoadhesive compositions and process of preparation thereof
JP2018517715A5 (https=)
Raju et al. Formulation and in-vitro evaluation of buccal tablets of metoprolol tartrate
JP2010523678A5 (https=)
CN101784263A (zh) 奈韦拉平的延长释放制剂
CN1658898B (zh) 包含培哚普利的口腔分散药物组合物
JP5064226B2 (ja) 不眠症の治療において有用な新規な製剤処方
US20150328277A1 (en) Oral transmucosal delivery of glatiramer acetate
KR101697773B1 (ko) 독소필린을 포함하는 변형 방출 조성물
TW200800155A (en) Gastric retentive gabapentin dosage forms and methods for using same
WO2019018338A1 (en) NASAL COMPOSITION COMPRISING A MUCOADHESIVE POLYMER
AU2013200682B1 (en) Fast Dissolving Solid Dosage Form
Tarun et al. Drug Delivery via the Buccal Patch-A Novel Approach
CN115531326A (zh) 一种卡巴拉汀微片及其制备方法
Doshi Preparation and evaluation of intraoral drug delivery system for the treatment of asthma
JP2003095936A (ja) 消化器用医薬組成物

Legal Events

Date Code Title Description
PB01 Publication
EXSB Decision made by sipo to initiate substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1214134

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20150826

WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1214134

Country of ref document: HK